New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 13, 2013
16:18 EDTTRGTTargacept sees FY13 revenue approximately $2.4M, consensus $2.95M
Expects its operating expenses for the year ending December 31 to be in the range of $48M-$54M and its cash, cash equivalents and investments balance at December 31 to be at least $135M. In addition, Targacept continues to expect that its current cash resources will be sufficient to meet its operating requirements at least through the end of 2015. This financial guidance includes both cash and non-cash revenue and expense items.
News For TRGT From The Last 14 Days
Check below for free stories on TRGT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 28, 2014
16:36 EDTTRGTTargacept discontinues TC-5214 development for overactive bladder
Targacept announced top-line results from a Phase 2b clinical trial of TC-5214 as a treatment for overactive bladder. In the trial, the high dose of TC-5214 demonstrated mixed results on the co-primary endpoints by providing a statistically significant reduction in micturition frequency and an improvement that did not reach statistical significance on episodes of urinary incontinence per 24 hours, after 12 weeks of treatment. As a consequence of these results, Targacept is discontinuing further development of TC-5214 in OAB. In this trial, TC-5214 was considered generally safe and well tolerated. However, there was a placebo corrected 15.1% rate of constipation and a 5.9% rate of urinary tract infection in the high dose group.
16:30 EDTTRGTTargacept trading halted, pending news
Subscribe for More Information
July 15, 2014
10:28 EDTTRGTHigh option volume stocks
High option volume stocks: TRGT ALB UUP ADHD ROC WWW CTRL KERX IMGN NI

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use